These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
212 related articles for article (PubMed ID: 25000592)
1. Efficacy of vaccination against influenza in patients with multiple sclerosis: The role of concomitant therapies. Pellegrino P; Carnovale C; Perrone V; Pozzi M; Antoniazzi S; Radice S; Clementi E Vaccine; 2014 Aug; 32(37):4730-5. PubMed ID: 25000592 [TBL] [Abstract][Full Text] [Related]
2. Balancing the benefits and risks of disease-modifying therapy in patients with multiple sclerosis. Sørensen PS J Neurol Sci; 2011 Dec; 311 Suppl 1():S29-34. PubMed ID: 22206763 [TBL] [Abstract][Full Text] [Related]
6. Functional improvement and symptom management in multiple sclerosis: clinical efficacy of current therapies. Berger JR Am J Manag Care; 2011 May; 17 Suppl 5 Improving():S146-53. PubMed ID: 21761953 [TBL] [Abstract][Full Text] [Related]
7. Treatment patterns in disease-modifying therapy for patients with multiple sclerosis in the United States. Bonafede MM; Johnson BH; Wenten M; Watson C Clin Ther; 2013 Oct; 35(10):1501-12. PubMed ID: 24139422 [TBL] [Abstract][Full Text] [Related]
8. Management of children with multiple sclerosis. Yeh EA Paediatr Drugs; 2012 Jun; 14(3):165-77. PubMed ID: 22497553 [TBL] [Abstract][Full Text] [Related]
10. Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies. Wingerchuk DM; Carter JL Mayo Clin Proc; 2014 Feb; 89(2):225-40. PubMed ID: 24485135 [TBL] [Abstract][Full Text] [Related]
11. Current disease-modifying therapies in multiple sclerosis. Kieseier BC; Hartung HP Semin Neurol; 2003 Jun; 23(2):133-46. PubMed ID: 12894379 [TBL] [Abstract][Full Text] [Related]
12. The therapy of multiple sclerosis with immune-modulating or immunosuppressive drug. A critical evaluation based upon evidence based parameters and published systematic reviews. Clerico M; Rivoiro C; Contessa G; Viglietti D; Durelli L Clin Neurol Neurosurg; 2008 Nov; 110(9):878-85. PubMed ID: 18164542 [TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and pharmacodynamics of the interferon-betas, glatiramer acetate, and mitoxantrone in multiple sclerosis. Neuhaus O; Kieseier BC; Hartung HP J Neurol Sci; 2007 Aug; 259(1-2):27-37. PubMed ID: 17391705 [TBL] [Abstract][Full Text] [Related]
14. [Pharmacological treatment of multiple sclerosis]. Myhr KM Tidsskr Nor Laegeforen; 2010 Mar; 130(5):490-2. PubMed ID: 20224616 [TBL] [Abstract][Full Text] [Related]
15. Seasonal and H1N1v influenza vaccines in MS: safety and compliance. Auriel E; Gadoth A; Regev K; Karni A J Neurol Sci; 2012 Mar; 314(1-2):102-3. PubMed ID: 22056469 [TBL] [Abstract][Full Text] [Related]
16. Combination therapy for the treatment of multiple sclerosis: challenges and opportunities. Stuart WH Curr Med Res Opin; 2007 Jun; 23(6):1199-208. PubMed ID: 17559719 [TBL] [Abstract][Full Text] [Related]
17. The current role of mitoxantrone in the treatment of multiple sclerosis. Cocco E; Marrosu MG Expert Rev Neurother; 2014 Jun; 14(6):607-16. PubMed ID: 24834466 [TBL] [Abstract][Full Text] [Related]
18. Current and future disease-modifying therapies in multiple sclerosis. Lim SY; Constantinescu CS Int J Clin Pract; 2010 Apr; 64(5):637-50. PubMed ID: 20456216 [TBL] [Abstract][Full Text] [Related]